William Potter, ACA

William Z. Potter, MD, Ph.D. is a world-renowned neuropsychiatric drug development expert who has achieved high level of success in NIMH as well as in industry. Dr. Potter most recently served as a Senior Advisor in Neuropsychiatry at NIMH. Previously, Dr. Potter was Vice President of Translational Neuroscience at Merck and, before that, Head of Early Clinical Development at Eli Lilly. Prior to working in the pharmaceutical industry, he had a distinguished career at the National Institutes of Health, primarily at NIMH. Dr. Potter was one of the early architects of the Alzheimer Disease Neuroimaging Initiative, and he continues as an active participant on the Industry Strategic Advisory Board. He is co-chair Emeritus of the NIH Biomarkers Consortium Neuroscience Steering Committee, where he has championed the collaborative development of both biochemical and cognitive measures to enhance drug development for Alzheimer's and other brain diseases. In addition, he serves on the Institute of Medicine Forum on Neuroscience. Dr. Potter has authored over 300 publications in neuroscience. He has deep experience in designing clinical development programs for a broad range of central nervous system disorders including and will provide advice in research and development decisions.

--